.jpg)
Chris is heading to the Spring NCCHC Conference in Louisville, KY to rep Diamond/OPTICS and give a presentation on overweight and obesity management in the correctional setting. As revolutionary weight loss treatments take hold in the community and in the popular consciousness, Chris is seizing on the moment not to just to talk about GLP-1s, but to review weight management as a whole, pharmocologic and non-pharmacologic treatments, special considerations for the corrections environment, and much more. We take a sneak peak at his presentation and talk about what he hopes attendees will take away from it.
Elswhere, we discuss:
The recent approval of Journavx for pain
Expanded Ozempic indication
RSV and Meningococcal vaccine updates
Rapid initiation approval for Sublocade
The elimination of the clozapine REMS program
And in our final trivia capsule segment, Chris highlights how venom from some very nasty beasties has been utilized to treat everything from hypertension to severe chronic pain.
Visit Chris (and Diamond Pharmacy) at the NCCHC Conference- Booth 500!
References/Further Reading:
Into the Clinic Segment:
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain
SUZETRIGINE (VX-548) PHASE 2 RESULTS IN PAINFUL LUMBOSACRAL RADICULOPATHY
FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD
FDA approves GSK’s pentavalent meningococcal vaccine
FDA approves rapid initiation of Sublocade for opioid use disorder
HIGHLIGHTS OF PRESCRIBING INFORMATION: SUBLOCADE
FDA Officially Removes REMS Requirement for Clozapine
Main Discussion:
Obesity Epidemic in U.S. Prison Populations: A Meta-Analysis and Review of the Literature
Weight gain during incarceration: systematic review and meta-analysis
Stress Exposure, Food Intake, and Emotional State
Trivia Capsule:
The life-saving medicines inspired by animals
